Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Neurocrine Biosciences (NBIX) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -14.04% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -63.16% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -58.34% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 97.17% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -87.09% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -14.91% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -86.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.09% |
| Dec 31, 2025 | -64.24% |
| Sep 30, 2025 | -92.49% |
| Jun 30, 2025 | -40.06% |
| Mar 31, 2025 | -84.41% |
| Dec 31, 2024 | -80.27% |
| Sep 30, 2024 | -87.64% |
| Jun 30, 2024 | -87.61% |
| Mar 31, 2024 | 338.05% |
| Dec 31, 2023 | 528.42% |
| Sep 30, 2023 | -43.24% |
| Jun 30, 2023 | -87.61% |
| Mar 31, 2023 | -982.36% |
| Dec 31, 2022 | -993.61% |
| Sep 30, 2022 | 985.17% |
| Jun 30, 2022 | 145.47% |
| Mar 31, 2022 | -84.25% |
| Dec 31, 2021 | -162.08% |
| Sep 30, 2021 | 2,019.23% |
| Jun 30, 2021 | 1,596.55% |